29 phenotypes from multigenic genotypes

Allelic Composition Genetic Background	Annotated Term	Reference
Cd28tm1Pjl/Cd28tm1Pjl Tnfrsf9tm1Byk/Tnfrsf9tm1Byk either: B6.Cg-Cd28tm1Pjl Tnfrsf9tm1Byk or C.Cg-Cd28tm1Pjl Tnfrsf9tm1Byk	abnormal class switch recombination	J:83722
	abnormal cytotoxic T cell physiology	J:83722
	decreased IgG1 level	J:83722
	decreased IgG2a level	J:83722
	decreased IgM level	J:83722
	decreased interleukin-12 secretion	J:83722
	decreased splenocyte proliferation	J:83722
	decreased susceptibility to type IV hypersensitivity reaction	J:83722
Faslpr/Faslpr Tnfrsf9tm1Byk/Tnfrsf9tm1Byk MRL.Cg-Tnfrsf9tm1Byk Faslpr	abnormal kidney morphology	J:126929
	abnormal lacrimal gland morphology	J:126929
	abnormal outer ear morphology	J:127197
	cortical renal glomerulopathies	J:127197
	enlarged lymph nodes	J:127197
	enlarged spleen	J:127197
	normal hematopoietic system phenotype	J:127197
	increased anti-nuclear antigen antibody level	J:127197
	increased B-1 B cell number	J:127197
	increased B-2 B cell number	J:127197
	increased CD4-positive, alpha-beta T cell number	J:126929, J:127197
	increased double-negative T cell number	J:126929, J:127197
	increased immunoglobulin level	J:127197
	increased interleukin-4 secretion	J:126929
	increased lacrimal gland apoptosis	J:126929
	increased spleen germinal center number	J:127197
	increased susceptibility to systemic lupus erythematosus	J:127197
	lacrimal gland inflammation	J:126929
	premature death	J:127197
	renal glomerular protein deposits	J:127197
	skin lesions	J:127197